Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755183 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
A Phase 2 study, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00755183 is a Phase 2 study that has completed, run by ORA. The registered enrollment target is 60 participants.
The verdict
NCT00755183, a Phase 2 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
Interventions
- DRUG testosterone ophthalmic solution
- DRUG vehicle of testosterone ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755183
The ClinicalTrials.gov registry entry for NCT00755183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which testosterone ophthalmic solution is the first listed.
NCT00755183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755183 about?
NCT00755183 is a clinical study titled "Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction". The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
What is the current status of trial NCT00755183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00755183?
The interventions under investigation include: testosterone ophthalmic solution (DRUG), vehicle of testosterone ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00755183?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.